Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1156
- Registration Number
- NCT06671912
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 4220
- Registration Number
- NCT06492616
- Locations
- 🇺🇸
Cancer Centers of Kansas, Wichita, Kansas, United States
🇺🇸Miami Valley Hospital South, Centerville, Ohio, United States
🇺🇸Virginia Cancer Institute, Mechanicsville, Virginia, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Brain Blood Flow Responses to Stress: Sex Differences
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 26
- Registration Number
- NCT06253702
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Region Örebro County
- Target Recruit Count
- 3832
- Registration Number
- NCT06223698
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪University Hospital of Umeå, Umeå, Sweden
🇸🇪Akademiska University Hospital Uppsala, Uppsala, Sweden
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Conditions
- Locally Advanced Unresectable HER2-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Locally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AnastrozoleProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic ImagingDrug: ExemestaneOther: Fludeoxyglucose F-18Drug: Fluorine F 18 Fluoro Furanyl NorprogesteroneDrug: FulvestrantBiological: Gonadotropin-releasing Hormone AnalogDrug: LetrozoleProcedure: Positron Emission TomographyDrug: TamoxifenDrug: Therapeutic Estradiol
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT06179303
- Locations
- 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of 18F-FFNP Breast PET/MRI
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 53
- Registration Number
- NCT06086704
- Locations
- 🇺🇸
UW Carbone Cancer Center, Madison, Wisconsin, United States
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- 🇺🇸
Texas Oncology Central, Austin, Texas, United States
🇺🇸Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06001762
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.